Endo Paget Bone Marker Liver Dysfunction

---
name: endo-paget-bone-marker-liver-dysfunction
description: Recommends measuring a specific bone formation or resorption marker in patients with Paget's disease who have abnormal liver or biliary tract function to assess treatment response or disease evolution. Triggered when liver function tests (e.g., ALT, AST, ALP, bilirubin) are abnormal in a patient with known Paget's disease.
---

# Measure specific bone turnover marker in liver dysfunction

## STEP 1 — Gather Information
Confirm diagnosis of Paget's disease via plain radiographs or radionuclide bone scan; obtain baseline liver function tests (ALT, AST, ALP, bilirubin, GGT).  
**Action:** Proceed to evaluate liver dysfunction.

## STEP 2 — Rule In / Rule Out
Determine if any liver function test is abnormal (ALT/AST >2× ULN, bilirubin >1.2 mg/dL, GGT elevated, or ALP disproportionate to bone disease).  
**Decision:** If abnormal, rule in liver dysfunction and move to Step 3; if normal, consider total ALP as the initial marker (outside this pathway).

## STEP 3 — Classify or Stratify
Select the specific bone turnover marker: prefer serum P1NP (bone formation) if available and affordable; otherwise use serum β‑CTx or urine NTx (resorption).  
**Action:** Order the chosen marker.

## STEP 4 — Decide
Obtain the selected marker at baseline and repeat every 3–6 months to monitor treatment response or disease evolution in untreated or treated patients.  
**Action:** Schedule follow‑up testing and adjust therapy based on marker trends.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on total ALP alone when liver dysfunction is present due to overlap with hepatic ALP; avoid interpreting marker changes without assay standardization; do not substitute symptoms for biochemical monitoring; consider renal clearance when using CTx assays.

## Concrete Clinical Example
A 68‑year‑old man with known pelvic Paget's disease and elevated ALT (68 U/L) and ALP (210 U/L) starts zoledronate; baseline P1NP is 78 µg/L. At 3 months, P1NP falls to 45 µg/L, indicating adequate treatment response.

**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910